Sitagliptin/metformin extended-release

Drug Profile

Sitagliptin/metformin extended-release

Alternative Names: Januet XR; Janumet XR; Metformin extended-release/sitagliptin; Metformin XR/sitagliptin; MK-0431A XR; Sitagliptin/metformin XR

Latest Information Update: 04 Dec 2015

Price : $50

At a glance

  • Originator Merck & Co
  • Class Antihyperglycaemics; Biguanides; Insulin sensitisers; Pyrazines; Small molecules; Triazoles
  • Mechanism of Action AMP activated protein kinase stimulants; CD26 antigen inhibitors; Gluconeogenesis inhibitors; Glucose modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 25 Sep 2015 Merck has patent protection for sitagliptin/metformin XR in USA (Merck 10-K, September 2015)
  • 03 Jun 2015 Launched for Type-2 diabetes mellitus in Israel, Malaysia, Singapore, Hong Kong and India (PO) before June 2015
  • 05 May 2015 Phase-III clinical trials in Type-2 diabetes mellitus (In adolescents, In children) in Ukraine, Taiwan, Sri Lanka, South Africa, Serbia, Russia, Philippines, Panama, New Zealand, Honduras, Costa Rica, Chile, Canada, Brazil and Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top